C-Met/Axl-IN-1

C-Met/Axl-IN-1 (Compound 22a) is an orally bioavailable, selective type II inhibitor targeting c-Met (IC50=1 nM) and Axl (IC50=10 nM) . It demonstrates potent anti-tumor activity by inhibiting proliferation, inducing cell cycle arrest, and promoting apoptosis in cellular assays, supporting its use in oncology research.